Caris expands its extensive network of leading
cancer institutions committed to improving patient outcomes through
innovations in precision medicine by welcoming the University of Mississippi Medical Center
IRVING,
Texas, July 25, 2024 /PRNewswire/ -- Caris Life
Sciences®(Caris), a leading next-generation AI TechBio
company and precision medicine pioneer, announced today that The
University of Mississippi Medical
Center (UMMC) has joined the Caris Precision Oncology
Alliance™ (Caris POA).
Caris expands its extensive network of
leading cancer institutions committed to improving patient
outcomes
The Caris POA is a growing network of leading cancer centers and
research consortia across the globe that collaborate to advance
precision oncology and biomarker-driven research, with its members
working together to establish and optimize standards of care for
molecular testing through innovative research to improve clinical
outcomes for cancer patients. POA members are uniquely positioned
to leverage Caris' highly sophisticated AI bioinformatics and
machine learning capabilities across Caris' massive multi-modal
database to enable innovative research to improve clinical outcomes
for cancer patients.
The University of Mississippi Medical
Center is the state's only academic medical center, with a
focus to improve the health of Mississippi's population and eliminate health
disparities through education, research and patient care. Their
three-part mission is to improve the lives of Mississippians by
educating tomorrow's health care professionals, conducting health
sciences research, and providing cutting-edge patient care. UMMC
encompasses six health science schools of medicine, nursing, health
related professions, dentistry, graduate studies and population
health.
"We are pleased to welcome the University
of Mississippi Medical Center into the growing Caris
Precision Oncology Alliance," said George
W. Sledge, Jr., MD, EVP and Chief Medical Officer of Caris.
"UMMC's commitment to cutting-edge therapy, clinical trials and
interdisciplinary collaboration makes them a valuable alliance
member. We're eager to collaborate with their investigators on our
shared mission of improving the outcomes of all patients affected
by cancer."
"The power of the Caris POA is that it provides UMMC access to
not only thousands of complete annotations and molecular profiling
data points for each patient, but also a network of investigators
and oncologists, both of which are powerful resources for cancer
researchers," said Rodney Rocconi,
MD, FACOG, director of the UMMC Cancer Center and Research
Institute and Ergon Chair for Cancer Research. "This cutting-edge
data will provide our physicians with immediate information at
their fingertips."
The Caris POA includes 95 cancer centers, academic institutions,
research consortia and healthcare systems. These institutions have
early access to the extensive database and artificial intelligence
platform within Caris to establish evidence-based standards for
cancer profiling and molecular testing in oncology. By leveraging
the comprehensive genomic, transcriptomic and proteomic profiling
available through Caris molecular profiling, Caris seeks to provide
this network with the ability to prioritize therapeutic options and
determine which clinical trial opportunities may benefit their
patients. POA members are also able to integrate with a growing
portfolio of biomarker-directed trials sponsored by biopharma.
Additionally, POA member institutions have access to one of the
largest and most comprehensive multi-modal databases in the
industry, which includes matched molecular and clinical outcomes
data from hundreds of thousands of cancer patients, covering tens
of billions of datapoints per patient.
About Caris Life Sciences
Caris Life
Sciences® (Caris) is a leading next-generation AI
TechBio company and precision medicine pioneer that is actively
developing and delivering innovative solutions to revolutionize
healthcare and improve the human condition. Through comprehensive
molecular profiling (Whole Exome and Whole Transcriptome
Sequencing) and the application of advanced AI and machine learning
algorithms, Caris has created the large-scale, multi-modal database
and computing capability needed to analyze and unravel the
molecular complexity of disease. This convergence of sequencing
power, big data and AI technologies provides an unmatched platform
to deliver the next generation of precision medicine tools for
early detection, diagnosis, monitoring, therapy selection and drug
development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Cambridge (MA),
Tokyo, Japan and Basel, Switzerland. Caris or its distributor
partners provide services in the U.S., Europe, Asia
and other international markets. To learn more, please visit
CarisLifeSciences.com.
About the University of Mississippi
Medical Center
As the state's only academic medical
center, UMMC seeks to improve the health of Mississippi's population and eliminate health
disparities through education, research and patient care. UMMC
encompasses six health science schools of medicine, nursing, health
related professions, dentistry, graduate studies and population
health. The Medical Center includes the state's only Level I trauma
center, only children's hospital, only organ and bone marrow
transplant program and the only Telehealth Center of Excellence,
one of two in the nation. For more information, visit
www.umc.edu.
Caris Life Sciences Media Contact:
Lisa Burgner
Corpcomm@CarisLS.com
214.294.5606
University of Mississippi Medical
Center Media Contact:
Jewell
Davis, PhD, MS
jdavis25@umc.edu
601.815.5718
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-the-university-of-mississippi-medical-center-302205403.html
SOURCE Caris Life Sciences